Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849667 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
A Phase 3 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
NCT00849667 is a Phase 3 study that was terminated before completion, run by Morphotek. The registered enrollment target is 1,100 participants.
The verdict
NCT00849667, a Phase 3 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
Study Summary
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
Interventions
- DRUG Carboplatin
- DRUG Taxane
- DRUG Farletuzumab
- DRUG Farletuzumab-matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2009-04-16 |
| Est. Completion | 2013-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849667
The ClinicalTrials.gov registry entry for NCT00849667 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00849667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00849667 about?
NCT00849667 is a clinical study titled "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse". This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
What is the current status of trial NCT00849667?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2009-04-16. Estimated completion is 2013-04-12.
What interventions are being tested in trial NCT00849667?
The interventions under investigation include: Carboplatin (DRUG), Taxane (DRUG), Farletuzumab (DRUG), Farletuzumab-matched placebo (DRUG).
Who is sponsoring clinical trial NCT00849667?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.